Novo Nordisk has filed legal action in the US to block the launch of Sanofi-Aventis' new Solo-Star insulin injection pen, The Financial Times reports.
Novo Nordisk is seeking an injunction because it claims Sanofi’s Solo-Star pen infringes on the patents on its NovoPen 4.
Sanofi-Aventis’ Solo-Star injection pen, which administers Lantus insulin, was recently approved by the FDA. Sanofi-Aventis launched Solo-Star in France and Germany in May and has plans to introduce it elsewhere across Europe and in the US in the months ahead.
Both insulin pens will be competing in a global insulin market worth up to $8.2 billion.
Sanofi-Aventis said in the Financial Times report that it disagreed with Novo Nordisk’s claims and would “vigorously defend” its rights.